Download MendeleyOptimization of potent, selective, and orally bioavailable pyrrolodinopyrimidine-containing inhibitors of heat shock protein 90. Identification of development candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide.
Zehnder, L., Bennett, M., Meng, J., Huang, B., Ninkovic, S., Wang, F., Braganza, J., Tatlock, J., Jewell, T., Zhou, J.Z., Burke, B., Wang, J., Maegley, K., Mehta, P.P., Yin, M.J., Gajiwala, K.S., Hickey, M.J., Yamazaki, S., Smith, E., Kang, P., Sistla, A., Dovalsantos, E., Gehring, M.R., Kania, R., Wythes, M., Kung, P.P.(2011) J Med Chem 54: 3368-3385
- PubMed: 21438541
- DOI: https://doi.org/10.1021/jm200128m
- Primary Citation of Related Structures:
3R4M, 3R4N, 3R4O, 3R4P - PubMed Abstract:
A novel class of heat shock protein 90 (Hsp90) inhibitors was discovered by high-throughput screening and was subsequently optimized using a combination of structure-based design, parallel synthesis, and the application of medicinal chemistry principles. Through this process, the biochemical and cell-based potency of the original HTS lead were substantially improved along with the corresponding metabolic stability properties. These efforts culminated with the identification of a development candidate (compound 42) which displayed desired PK/PD relationships, significant efficacy in a melanoma A2058 xenograft tumor model, and attractive DMPK profiles.
Organizational Affiliation:
La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States.
